Precision Oncology – Tailoring Treatments for Better Outcomes
Precision Oncology – Tailoring Treatments for Better Outcomes Read More »
Randomized clinical trials (RCTs) began in the 1940s with streptomycin’s evaluation against tuberculosis. Since then, RCTs have been the foundation of clinical trial design, ensuring therapies reach patients safely. For decades, oncology trials followed a set pattern: drugs were tested in preclinical models, followed by dose escalation to assess safety, toxicity, and efficacy compared to
Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research Read More »
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models One of the most significant areas of advancement in oncology is the growing capacity to match patients with therapies tailored to their unique cancer. As more relevant biomarkers and druggable targets are identified, drug developers still face an evergreen challenge: narrowing down the most
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models Read More »
Accelerating Targeted Cancer Therapy Trials: Perspectives from START Key Highlights Significant increase in FDA-approved targeted cancer therapies over the past decade. Low prevalence of specific mutations and variable toxicities of targeted therapies are important challenges to consider when starting a trial. Selecting sites with expertise is crucial to timely completion of trials with accurate reporting.
Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies Read More »
Hope in His Backyard: Rickie’s Cancer Journey with START Midwest Growing up in Grand Rapids, Michigan, Rickie’s life was what you might expect for someone growing up in the Midwest. He played sports throughout high school and college and worked for General Motors for 31 years before retiring to take up a part-time job picking
Hope in His Backyard: Rickie’s Cancer Journey with START Read More »
The START Center for Cancer Research represents a global team of leading investigators in medical oncology, driven by a commitment to improving clinical trial access for patients treated in community oncology centers. Emiliano Calvo, MD, PhD, and Victor Moreno, MD, PhD, serve as Directors of Clinical Research at START Madrid-CIOCC and START Madrid-FJD, respectively. As
Driving Oncology Research Progress Through Access to Early-Phase Trials Read More »